Advanced Cell Technology’s Dr. Robert Lanza Testifies Before U.S. Senate Subcommittee; Testimony Discusses How Company’s Technique For Human Stem Cell Development May Advance Support For Stem Cell Research

WORCESTER, Mass.--(BUSINESS WIRE)--Sept. 6, 2006--Advanced Cell Technology, Inc. (OTCBB:ACTC) today announced that Robert Lanza, M.D., Advanced Cell Technology’s Vice President of Medical and Stem Cell Development, testified today before the Senate Labor, Health & Human Services and Education Appropriations Subcommittee. Dr. Lanza’s testimony focused on support for wider availability of human embryonic stem cells for basic medical research. Dr. Lanza is the principle author of a paper published online (ahead of print) on August 23 in the peer-reviewed journal Nature, which described a technique for developing human embryonic stem cells with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). This technique is not harmful to embryos.

MORE ON THIS TOPIC